Education
About Us
Working with TipRanks
Follow Us
Consun Pharmaceutical Group Ltd. (HK:1681)
:1681
RESEARCH TOOLSreports
1681 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$5.26 - HK$9.30
Previous CloseN/A
Volume1.82M
Average Volume (3M)1.43M
Market Cap
HK$7.43B
Enterprise ValueHK$1.53B
Total Cash (Recent Filing)¥1.27B
Total Debt (Recent Filing)¥392.54M
Price to Earnings (P/E)7.4
Beta0.54
Next Earnings
Aug 21, 2025EPS EstimateN/A
Next Dividend Ex-Date
Jun 10, 2025Dividend Yield7.84%
Share Statistics
EPS (TTM)1.20
Shares Outstanding849,513,100
10 Day Avg. Volume1,676,866
30 Day Avg. Volume1,425,209
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)N/A
Price to Sales (P/S)1.52
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.02Price Target Upside11.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Consun Pharmaceutical Group Ltd. News
PremiumCompany Announcements
Consun Pharmaceutical Appoints Renowned Nephrologist as Scientific Advisor
PremiumCompany Announcements
Consun Pharmaceutical Declares Final Dividend for 2024
PremiumCompany Announcements
Consun Pharmaceutical Advances CKD Treatment with SK-08 Tablet Trial
PremiumCompany Announcements
Consun Pharmaceutical Announces Board and Management Reshuffle
PremiumCompany Announcements
Consun Pharma Passes Key Governance Resolution---
Bulls Say, Bears Say
Bulls Say
Dividend PayoutDividend payout increased by 10ppts to 51% in 2024, with the higher payout expected to continue given solid financial position, translating into an attractive yield of 7%+.
Product PenetrationFurther penetration of uremic clearance granules in hospitals is expected to drive EPS growth, with significant penetration already achieved in top-tier hospitals.
Sales GrowthPotential introduction of new drugs, with focus areas being identified, could be a catalyst and drive sales growth ahead.
Bears Say
Economic SlowdownSales volume growth slowdown due to a slowing economy.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
3.68%
Mutual Funds
― Other Institutional Investors
94.62% Public Companies and
Individual Investors
1681 FAQ
What was Consun Pharmaceutical Group Ltd.’s price range in the past 12 months?
Consun Pharmaceutical Group Ltd. lowest stock price was HK$5.26 and its highest was HK$9.30 in the past 12 months.
What is Consun Pharmaceutical Group Ltd.’s market cap?
Consun Pharmaceutical Group Ltd.’s market cap is HK$7.43B.
When is Consun Pharmaceutical Group Ltd.’s upcoming earnings report date?
Consun Pharmaceutical Group Ltd.’s upcoming earnings report date is Aug 21, 2025 which is in 142 days.
How were Consun Pharmaceutical Group Ltd.’s earnings last quarter?
Consun Pharmaceutical Group Ltd. released its earnings results on Mar 26, 2025. The company reported HK$0.662 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.662.
Is Consun Pharmaceutical Group Ltd. overvalued?
According to Wall Street analysts Consun Pharmaceutical Group Ltd.’s price is currently Undervalued.
Does Consun Pharmaceutical Group Ltd. pay dividends?
Consun Pharmaceutical Group Ltd. pays a Annually dividend of HK$0.3 which represents an annual dividend yield of 7.84%. See more information on Consun Pharmaceutical Group Ltd. dividends here
What is Consun Pharmaceutical Group Ltd.’s EPS estimate?
Consun Pharmaceutical Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Consun Pharmaceutical Group Ltd. have?
Consun Pharmaceutical Group Ltd. has 849,513,100 shares outstanding.
What happened to Consun Pharmaceutical Group Ltd.’s price movement after its last earnings report?
Consun Pharmaceutical Group Ltd. reported an EPS of HK$0.662 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.678%.
Which hedge fund is a major shareholder of Consun Pharmaceutical Group Ltd.?
Currently, no hedge funds are holding shares in HK:1681
---
Company Description
Consun Pharmaceutical Group Ltd.
Consun Pharmaceutical Group is a biotechnology company with sales operations throughout China. Its principal activities are making and selling pharmaceutical products. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast medium, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
---
1681 Stock 12 Month Forecast
Average Price Target
HK$10.02
▲(11.96% Upside)
Technical Analysis
Sino Biopharmaceutical
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
China Resources Pharmaceutical Group Ltd.
―
Best Analysts Covering 1681
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
-3.13%
reiterated a buy rating 6 days ago
Copying Mark Kong CFA's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of -3.13% per trade.
---